Literature DB >> 21956690

Current progress in the development of RNAi-based therapeutics for HIV-1.

J Zhou1, J J Rossi.   

Abstract

Highly active antiretroviral therapy (HAART) treatment for HIV has changed the course of AIDS in societies in which the drugs are readily available. Despite the great success of HAART, drug resistance and toxicity issues still remain a concern for some individuals. Thus, a number of investigators have been exploring other approaches for inhibiting HIV-1 replication. One of the most potent of these is the use of RNA interference (RNAi). This review will focus solely on the use of RNAi for the treatment of HIV-1 infection, including the problems, progress and future prospects.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21956690      PMCID： PMC3388903          DOI： 10.1038/gt.2011.149

Source DB:  PubMed          Journal:  Gene Ther        ISSN： 0969-7128            Impact factor:   5.250


  46 in total

1.  RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals.

Authors:  P D Zamore; T Tuschl; P A Sharp; D P Bartel
Journal:  Cell       Date:  2000-03-31       Impact factor: 41.582

2.  Nucleotide sequence homology requirements of HIV-1-specific short hairpin RNA.

Authors:  Oliver Pusch; Daniel Boden; Rebecca Silbermann; Fred Lee; Lynne Tucker; Bharat Ramratnam
Journal:  Nucleic Acids Res       Date:  2003-11-15       Impact factor: 16.971

3.  A soluble CD4 protein selectively inhibits HIV replication and syncytium formation.

Authors:  R E Hussey; N E Richardson; M Kowalski; N R Brown; H C Chang; R F Siliciano; T Dorfman; B Walker; J Sodroski; E L Reinherz
Journal:  Nature       Date:  1988-01-07       Impact factor: 49.962

4.  An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection.

Authors:  M R Posner; T Hideshima; T Cannon; M Mukherjee; K H Mayer; R A Byrn
Journal:  J Immunol       Date:  1991-06-15       Impact factor: 5.422

5.  RNA interference targeting Fas protects mice from fulminant hepatitis.

Authors:  Erwei Song; Sang-Kyung Lee; Jie Wang; Nedim Ince; Nengtai Ouyang; Jun Min; Jisheng Chen; Premlata Shankar; Judy Lieberman
Journal:  Nat Med       Date:  2003-02-10       Impact factor: 53.440

6.  Human immunodeficiency virus type 1 escape from RNA interference.

Authors:  Daniel Boden; Oliver Pusch; Frederick Lee; Lynne Tucker; Bharat Ramratnam
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

7.  The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.

Authors:  A G Dalgleish; P C Beverley; P R Clapham; D H Crawford; M F Greaves; R A Weiss
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

8.  Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition.

Authors:  Atze T Das; Thijn R Brummelkamp; Ellen M Westerhout; Monique Vink; Mandy Madiredjo; René Bernards; Ben Berkhout
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

9.  Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy.

Authors:  Jiehua Zhou; Haitang Li; Shirley Li; John Zaia; John J Rossi
Journal:  Mol Ther       Date:  2008-05-06       Impact factor: 11.454

Review 10.  The role of CD4 in HIV binding and entry.

Authors:  Q J Sattentau; J P Moore
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1993-10-29       Impact factor: 6.237
View more
  20 in total

Review 1.  Regulation of small RNA stability: methylation and beyond.

Authors:  Lijuan Ji; Xuemei Chen
Journal:  Cell Res       Date:  2012-03-13       Impact factor: 25.617

2.  Injection parameters and virus dependent choice of promoters to improve neuron targeting in the nonhuman primate brain.

Authors:  W Lerchner; B Corgiat; V Der Minassian; R C Saunders; B J Richmond
Journal:  Gene Ther       Date:  2014-01-09       Impact factor: 5.250

3.  RNA aptamers and their therapeutic and diagnostic applications.

Authors:  Katherine Germer; Marissa Leonard; Xiaoting Zhang
Journal:  Int J Biochem Mol Biol       Date:  2013-03-31

Review 4.  Recent advances in RNAi-based strategies for therapy and prevention of HIV-1/AIDS.

Authors:  Manjunath N Swamy; Haoquan Wu; Premlata Shankar
Journal:  Adv Drug Deliv Rev       Date:  2016-03-21       Impact factor: 15.470

Review 5.  Protein and oligonucleotide delivery systems for vaginal microbicides against viral STIs.

Authors:  Jill M Steinbach
Journal:  Cell Mol Life Sci       Date:  2014-10-17       Impact factor: 9.261

6.  A New Approach for the Treatment of Arthritis in Mice with a Novel Conjugate of an Anti-C5aR1 Antibody and C5 Small Interfering RNA.

Authors:  Gaurav Mehta; Robert I Scheinman; V Michael Holers; Nirmal K Banda
Journal:  J Immunol       Date:  2015-04-27       Impact factor: 5.422

7.  siRNA against KIR3DL1 as a potential gene therapeutic agent in controlling HIV-1 infection.

Authors:  Geng-Feng Fu; Ji-Cheng Pan; Nan Lin; Hai-Yang Hu; Wei-Ming Tang; Jin-Shui Xu; Xiao-Liang Wang; Xiao-Qin Xu; Tao Qiu; Xiao-Yan Liu; Guo-Hong Chen; Tanmay Mahapatra; Xi-Ping Huan; Hai-Tao Yang
Journal:  Viral Immunol       Date:  2014-05-16       Impact factor: 2.257

8.  RNase P-associated external guide sequence effectively reduces the expression of human CC-chemokine receptor 5 and inhibits the infection of human immunodeficiency virus 1.

Authors:  Wenbo Zeng; Gia-Phong Vu; Yong Bai; Yuan-Chuan Chen; Phong Trang; Sangwei Lu; Gengfu Xiao; Fenyong Liu
Journal:  Biomed Res Int       Date:  2012-12-27       Impact factor: 3.411

9.  Engineering HIV-1-resistant T-cells from short-hairpin RNA-expressing hematopoietic stem/progenitor cells in humanized BLT mice.

Authors:  Gene-Errol E Ringpis; Saki Shimizu; Hubert Arokium; Joanna Camba-Colón; Maria V Carroll; Ruth Cortado; Yiming Xie; Patrick Y Kim; Anna Sahakyan; Emily L Lowe; Munetoshi Narukawa; Fadi N Kandarian; Bryan P Burke; Geoff P Symonds; Dong Sung An; Irvin S Y Chen; Masakazu Kamata
Journal:  PLoS One       Date:  2012-12-31       Impact factor: 3.240

10.  Effective inhibition of human immunodeficiency virus 1 replication by engineered RNase P ribozyme.

Authors:  Wenbo Zeng; Yuan-Chuan Chen; Yong Bai; Phong Trang; Gia-Phong Vu; Sangwei Lu; Jianguo Wu; Fenyong Liu
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.